We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bed Bath & Beyond Inc. posted rough second quarter results on September 30 and issued lower-than-projected guidance in the face of supply chain worries and more.
The Basics
Bed Bath & Beyond is a larger retailer that competes in the home-based spending space alongside companies like Target (TGT - Free Report) and others. Despite solid overall conditions, BBBY’s sales have slipped in the last few years and its recently-reported Q2 revenue tumbled 26%.
Bed Bath & Beyond’s adjusted earnings dropped from $0.50 a share in the year-ago quarter to $0.04, which also missed our Zacks estimate by 92%. The company cited supply chain setbacks, rising costs, the delta variant, marketing missteps, and more as reasons for the disappointing quarter. And the situation doesn’t appear to be getting better in the near-term.
Zacks estimates call for BBBY’s third quarter sales to fall 24% and Q4 to come in 12% lower. Its overall fiscal 2021 revenue is projected to fall by nearly 11% and FY22 is only expected to come in marginally (0.25%) above its current tough year.
Image Source: Zacks Investment Research
Bottom Line
BBBY shares tumbled following its second quarter results and disappointing guidance, with it now down around 45% in the past month alone. The nearby chart shows the stock is in the midst of a much longer underperformance, having fallen 67% in the last five years.
Bed Bath & Beyond’s FY21 and FY22 consensus earnings estimates have plummeted by 31% and 25%, respectively since its report. These downward EPS revisions help it land a Zacks Rank #5 (Strong Sell) at the moment. Therefore, it might be best to stay away from BBBY stock for now.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Bear of the Day: Bed Bath & Beyond Inc. (BBBY)
Bed Bath & Beyond Inc. posted rough second quarter results on September 30 and issued lower-than-projected guidance in the face of supply chain worries and more.
The Basics
Bed Bath & Beyond is a larger retailer that competes in the home-based spending space alongside companies like Target (TGT - Free Report) and others. Despite solid overall conditions, BBBY’s sales have slipped in the last few years and its recently-reported Q2 revenue tumbled 26%.
Bed Bath & Beyond’s adjusted earnings dropped from $0.50 a share in the year-ago quarter to $0.04, which also missed our Zacks estimate by 92%. The company cited supply chain setbacks, rising costs, the delta variant, marketing missteps, and more as reasons for the disappointing quarter. And the situation doesn’t appear to be getting better in the near-term.
Zacks estimates call for BBBY’s third quarter sales to fall 24% and Q4 to come in 12% lower. Its overall fiscal 2021 revenue is projected to fall by nearly 11% and FY22 is only expected to come in marginally (0.25%) above its current tough year.
Bottom Line
BBBY shares tumbled following its second quarter results and disappointing guidance, with it now down around 45% in the past month alone. The nearby chart shows the stock is in the midst of a much longer underperformance, having fallen 67% in the last five years.
Bed Bath & Beyond’s FY21 and FY22 consensus earnings estimates have plummeted by 31% and 25%, respectively since its report. These downward EPS revisions help it land a Zacks Rank #5 (Strong Sell) at the moment. Therefore, it might be best to stay away from BBBY stock for now.